Takeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Takeda is launching an international chart review to better understand long-term treatment of people with congenital thrombotic thrombocytopenic purpura, or cTTP, who received its recombinant ADAMTS13 enzyme under an early access program. The study will track health impact, treatment patterns, and pregnancy outcomes before and after exposure to the product, adding real‑world support around this rare disease asset.

The treatment under review is recombinant ADAMTS13, a lab-made version of a natural blood enzyme used to reduce harmful clot formation in small vessels. It is given to replace missing or low enzyme activity in cTTP, with the goal of preventing life‑threatening clotting episodes and improving daily functioning in a very small patient population.

This is an observational, non-interventional study that only reviews data already captured in medical records, with no new drugs assigned by the protocol. Researchers will follow a cohort of patients in a retrospective manner, comparing their clinical course and treatment use before and after starting recombinant ADAMTS13 to build a clearer picture of its real‑world value.

The study was first submitted on 28 January 2026 and is currently listed as not yet recruiting, signaling that sites are being prepared and records identified. Takeda expects enrollment and data collection to wrap up by late 2026, and the most recent update on 11 March 2026 confirms that planning and set‑up remain active.

For investors, this update supports Takeda’s rare disease franchise and could strengthen the case for broader uptake or pricing resilience if outcomes look favorable. Positive real‑world data may also sharpen Takeda’s edge against future enzyme or gene-based rivals in ultra-rare hematology, though near-term revenue impact is likely modest given the very small cTTP market.

The study remains active in set-up with further details and ongoing updates available on the ClinicalTrials portal.

To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.

Disclaimer & DisclosureReport an Issue